Safety and Pharmacokinetics of Motesanib in Combination with Panitumumab and Gemcitabine-Cisplatin in Patients with Advanced Cancer

Table 1

Demographic and baseline clinical characteristics of study patients.

		Motesanib dose cohort
	0 mg QD (𝑛=8)	50 mg QD (𝑛=8)	75 mg QD (𝑛=6)	100 mg QD (𝑛=6)	125 mg QD (𝑛=11)	75 mg BID (𝑛=2)
Female, 𝑛 (%)	4 (50)	3 (38)	2 (33)	4 (67)	5 (45)	0 (0)
Male, 𝑛 (%)	4 (50)	5 (62)	4 (67)	2 (33)	6 (55)	2 (100)
Race, 𝑛 (%)
White	6 (75)	7 (88)	4 (67)	6 (100)	11 (100)	2 (100)
Black	1 (13)	1 (13)	2 (33)	0 (0)	0 (0)	0 (0)
Hispanic or Latino	1 (13)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Median age, 𝑦 (range)	52 (40–72)	65.5 (32–73)	57 (36–73)	52.5 (36–72)	63 (42–70)	65 (53–77)
ECOG performance status, 𝑛 (%)
0	6 (75)	3 (38)	1 (17)	5 (83)	6 (55)	1 (50)
1	2 (25)	5 (63)	5 (83)	1 (17)	5 (45)	1 (50)
Tumor type, 𝑛 (%)
Non–small-cell lung	3 (38)	5 (63)	3 (50)	4 (67)	4 (36)	2 (100)
Pancreatic	3 (38)	0 (0)	0 (0)	0 (0)	2 (18)	0 (0)
Esophageal	1 (13)	1 (13)	1 (17)	0 (0)	0 (0)	0 (0)
Bladder	0 (0)	0 (0)	0 (0)	0 (0)	2 (18)	0 (0)
Breast	0 (0)	0 (0)	0 (0)	2 (33)	0 (0)	0 (0)
Kidney	0 (0)	0 (0)	0 (0)	0 (0)	1 (9)	0 (0)
Ovarian	1 (13)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Other	0 (0)	1 (13)	0 (0)	0 (0)	2 (18)	0 (0)
Unknown	0 (0)	1 (13)	2 (33)	0 (0)	0 (0)	0 (0)
Number of sites of disease, 𝑛 (%)a
0	1 (13)	1 (13)	1 (17)	0 (0)	1 (9)	0 (0)
1	3 (38)	2 (25)	1 (17)	3 (50)	3 (27)	1 (50)
2	4 (50)	5 (63)	3 (50)	2 (33)	5 (45)	1 (50)
3	0 (0)	0 (0)	1 (17)	1 (17)	2 (18)	0 (0)
Prior chemotherapy, 𝑛 (%)
0	6 (75)	4 (50)	5 (83)	4 (67)	10 (91)	2 (100)
1	2 (25)	4 (50)	1 (17)	2 (33)	1 (9)	0 (0)
Prior radiation therapy, 𝑛 (%)
0	6 (75)	3 (38)	4 (67)	4 (67)	8 (73)	1 (50)
1	0 (0)	4 (50)	1 (17)	1 (17)	3 (27)	0 (0)
2	2 (25)	1 (13)	1 (17)	1 (17)	0 (0)	1 (50)
3	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

BID: twice daily; ECOG: Eastern Cooperative Oncology Group; QD: once daily.
aAs assessed by investigator.